Literature DB >> 20711172

Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.

Ossama Abbas1, Joanna E Richards, Meera Mahalingam.   

Abstract

Microscopically, differentiating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma can be difficult as both show 'islands and strands of basaloid cells embedded in a sclerotic stroma'. A superficial shave biopsy further compounds the diagnostic conundrum. Although a plethora of immunohistochemical markers have been touted as being of use as adjunct histologic tools, none thus far appears to be consistent and reliable in terms of specificity and/or sensitivity. Fibroblast-activation protein, a type II membrane-bound glycoprotein belonging to the serine protease family, is expressed in the granulation tissue of healing wounds. More recently, it has been identified as a marker of reactive tumor stromal fibroblasts, as it is reportedly selectively expressed in peritumoral stromal fibroblasts of multiple epithelial cancers including cutaneous malignancies such as basal cell carcinoma. Given this, we sought to ascertain the use of fibroblast-activation protein in distinguishing morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Immunohistochemical staining for fibroblast-activation protein was performed on desmoplastic trichoepithelioma (n=25) and morpheaform/infiltrative basal cell carcinoma (n=25), with the control group comprising scars from reexcision specimens (n=10). As expected, fibroblast-activation protein expression was observed in stromal fibroblasts of all control cases (10 of 10, 100%). Of interest, fibroblast-activation protein expression was observed in peritumoral fibroblasts of all cases of morpheaform/infiltrative basal cell carcinoma (25 of 25, 100%) but not in any cases of desmoplastic trichoepithelioma (0 of 25, 0%). A gradient of fibroblast-activation protein expression was observed in morpheaform/infiltrative basal cell carcinoma with more intense expression noted in fibroblasts abutting the tumor cells, a less intense expression in the distal peritumoral stromal portion, and minimal to loss of expression in adjacent normal tissue. In summary, findings from this study underscore the use of fibroblast-activation protein as a histologic adjunct in confidently differentiating morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711172     DOI: 10.1038/modpathol.2010.142

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

2.  Dermal changes in superficial basal cell carcinoma, melanoma in situ and actinic keratosis and their implications.

Authors:  Viktoryia Kazlouskaya; Saurabh Malhotra; Raquel Navarro; Karen Nguyen Wu; Marianna Shvartsbeyn; Chen Shengli; Jiang Gui; Dirk M Elston
Journal:  J Cutan Pathol       Date:  2013-10-03       Impact factor: 1.587

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 4.  Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.

Authors:  Mihaela Aldea; Ioan Alexandru Florian; Gabriel Kacso; Lucian Craciun; Sanda Boca; Olga Soritau; Ioan Stefan Florian
Journal:  Pharm Res       Date:  2016-05-26       Impact factor: 4.200

5.  Desmoplastic trichoepithelioma: A clinicopathological study of three cases and a review of the literature.

Authors:  Qiongyu Wang; Deepak Ghimire; Juan Wang; Suju Luo; Zhengxiao Li; Hao Wang; Songmei Geng; Shengxiang Xiao; Yan Zheng
Journal:  Oncol Lett       Date:  2015-07-21       Impact factor: 2.967

Review 6.  Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives.

Authors:  Marianela Zambrano-Román; Jorge R Padilla-Gutiérrez; Yeminia Valle; José F Muñoz-Valle; Emmanuel Valdés-Alvarado
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

7.  Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment.

Authors:  Christian F Guerrero-Juarez; Gun Ho Lee; Yingzi Liu; Shuxiong Wang; Matthew Karikomi; Yutong Sha; Rachel Y Chow; Tuyen T L Nguyen; Venus Sosa Iglesias; Sumaira Aasi; Michael L Drummond; Qing Nie; Kavita Sarin; Scott X Atwood
Journal:  Sci Adv       Date:  2022-06-10       Impact factor: 14.957

8.  [SP13786 Inhibits the Migration and Invasion of Lung Adenocarcinoma Cell A549 
by Supressing Stat3-EMT via CAFs Exosomes].

Authors:  Shushu Wang; Jiayu Cui; Kaijia Zhang; Jinhua Gu; Yuanhang Zheng; Baogang Zhang; Lihong Shi
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-24

9.  Transformable Peptide Nanocarriers for Expeditious Drug Release and Effective Cancer Therapy via Cancer-Associated Fibroblast Activation.

Authors:  Tianjiao Ji; Ying Zhao; Yanping Ding; Jing Wang; Ruifang Zhao; Jiayan Lang; Hao Qin; Xiaoman Liu; Jian Shi; Ning Tao; Zhihai Qin; Guangjun Nie; Yuliang Zhao
Journal:  Angew Chem Int Ed Engl       Date:  2015-08-17       Impact factor: 15.336

Review 10.  Non-Melanoma Skin Cancers: Biological and Clinical Features.

Authors:  Mauro Cives; Francesco Mannavola; Lucia Lospalluti; Maria Chiara Sergi; Gerardo Cazzato; Elisabetta Filoni; Federica Cavallo; Giuseppe Giudice; Luigia Stefania Stucci; Camillo Porta; Marco Tucci
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.